Development of a genetic model predicting the carrier status for mmr-gene mutations Fabio Marroni 1, Piero Benatti 2, Mariapina Montera 3, Daniela Barana.

Slides:



Advertisements
Similar presentations
Clinical background: Patient RM, YoB 1966 Her family were originally referred because of a history of breast and ovarian cancer. BRCA testing found a missense.
Advertisements

Linkage analysis Nasir Mehmood Roll No: Linkage analysis Linkage analysis is statistical method that is used to associate functionality of genes.
Ivan P. Gorlov, Olga Y. Gorlova & Christopher I. Amos.
Universal Screening of Lynch Syndrome Heather Hampel, MS, CGC Clinical Associate Professor, Division of Human Genetics.
Lynch Syndrome and Colorectal Cancer Steven G. Proshan, M.D. Annapolis Colon and Rectal Surgeons Anne Arundel Medical Center November 8,
Risk Assessment for HNPCC
COLORECTAL BLEEDING: a multidisciplinary approach Torino, 31 marzo-1 aprile 2006 GENETIC EVALUATION Schena M, Angelini F, Bertetto O. Department of Medical.
The Genetics of Breast and Ovarian Cancer Susceptibility Patricia Tonin, PhD Associate Professor Depts. Medicine, Human Genetics & Oncology McGill University.
Lecture 22 Cancer Genetics II: Inherited Susceptibility to Cancer Stephen B. Gruber, MD, PhD November 19, 2002.
Mechanisms and Epidemiology of Colon Cancer
© 2001 Myriad Genetic Laboratories Northern Nevada Genetic Counseling Robbin Palmer Certified Genetic Counselor
Hereditary Colorectal Cancer: An Overview Felice Schnoll-Sussman,MD Jay Monahan Center for Gastrointestinal Health New York Hospital/ Weill Cornell Medical.
Hereditary ovarian/breast cancers (HOC/HBOC) Chair and Department of Surgical Gynecology and Gynecological Oncology of Adults and Adolescents. Head: Prof.
Breast Cancer Risk and Risk Assessment Models
About these slides SPEC – Short Presentation in Emerging Concepts
Familial Colorectal Cancers Francis M. Giardiello, M.D. The Johns Hopkins University.
Estimating the penetrances of breast and ovarian cancer in the carriers of BRCA1/2 mutations Silvano Presciuttini University of Pisa, Italy.
Comprehensive IHC Screening for Lynch Syndrome: What You Need to Know Andrea Lewis, MS, CGC January 14, 2010.
Genetic Susceptibility Risk Models in Clinical Decision Making Susan M. Domchek, MD Abramson Cancer Center University of Pennsylvania.
Type Of Cancer:Location: CarcinomaEpithelial Cells SarcomaConnective Tissue LeukemiaCirculatory / Lymphatic.
ESTIMATING CANCER PENETRANCES FROM GENETIC TEST RESULTS: Analysis of the Families from the Italian Registry of Hereditary Breast/ovarian Cancer Fabio Marroni,
PERFORMANCE OF DIFFERENT MODELS PREDICTING THE PRE-TEST PROBABILITY OF CARRYING MUTATIONS IN BRCA1 OR BRCA2 IN 330 ITALIAN FAMILIES Silvano Presciuttini,
IGES 2003 How many markers are necessary to infer correct familial relationships in follow-up studies? Silvano Presciuttini 1,3, Chiara Toni 2, Fabio Marroni.
Cancer Genetics for Primary Care Sara Levene Registered Genetic Counsellor.
BRCA2 Blue: Rad51; Green: BRCA2
An Accurate Genetic Model for Predicting the Carrier Status of mmr-gene Mutations Fabio Marroni 1, Piero Benatti 2, Mariapina Montera 3, Daniela Barana.
GENOME-WIDE LINKAGE SCAN IN A LARGE FAMILY WITH SUSPECTED GENETIC PREDISPOSITION TO CANCER Marroni F. 1, Lipkin S. 2, Benatti P. 3, Pedroni M. 3, Bailey-Wilson.
BRCA1 and BRCA2 Mutations and Breast Cancer: An Integrated Approach Using Four Epidemiologic Parameters Monica McClain, PhD. Assistant Director, Biometry.
Breast Screening. NHS Breast Screening Programme Introduced in 1988 Invites women from age group for screening every 3 yrs. Age extension roll-out.
BRCA1/2 Mutation Testing and Breast/Ovarian Cancer in the Ashkenazi Jewish Population Glenn E Palomaki, B.S. Foundation for Blood Research Scarborough,
© Dr Whitcomb Familial Pancreatic Cancer Families (and other high-risk people) David C Whitcomb MD PhD Giant Eagle Foundation Professor of Cancer Genetics.
Chapter 10 Molecular Diagnosis. Keypoints Identification of the gene for a disorder permits diagnostic testing by direct mutation analysis. Some genetic.
DNA Repair and Cancer. Genome Instability Science, 26 July 2002, p. 544.
1Day 2 Section 7 Introduction to survival analysis.
Chapter 13 Carrier Screening. Introduction Carrier screening involves testing of individuals for heterozygosity for genes that would produce significant.
Genetic-Environmental Interaction: Implications for Osteoporosis Prevention Strategies.
Tumour Analysis-Lynch Syndrome Dr Alan Donaldson Consultant in Clinical Genetics Bristol.
Familial Risk and Surveillance of Colon and Rectum Malcolm Dunlop Academic Coloproctology & Colon Cancer Genetics Group University of Edinburgh & Western.
Shiva Sharma SHO to Professor Redmond.  Introduction  Increased risk groups  Consideration of genetic testing  Management of patients with mutation.
BOadicea Antonis Antoniou Cancer Research - UK
What are Microsatellites? D2S123 TAGGCCACACACACACACACA Unique Primer Mono, di, tri, tetra nucleotide repeats HNPCC - Expansion/contraction of nl repeats.
Bonny Blackard Biology 169 April 4, 2006
Uterine Cancer Endometrial (or uterine) cancer will account for 50,000 new cases and 8200 deaths in the United States in Two genetic disorders are.
Genetic predisposition to
A GENETIC MODEL FOR PREDICTING THE CARRIER STATUS OF MSH2/MLH1 MUTATIONS: RESULTS OF AN ITALIAN MULTICENTER STUDY F. Marroni 1,2, P. Benatti 3, A. Viel.
Introduction Hereditary predisposition (mutations in BRCA1 and BRCA2 genes) contribute to familial breast cancers. Eighty percent of the.
1 LYNCH SYNDROME EPCAM FAMILY WITH PREDOMINANT COLORECTAL CANCER HENRY T. LYNCH, MD; STEPHEN N. THIBODEAU, PHD; CARRIE SNYDER, MSN, RN, APNG; JENNIFER.
Logistic Regression. Linear regression – numerical response Logistic regression – binary categorical response eg. has the disease, or unaffected by the.
Genetic disorders can be due to any of the following factors: A. Monogenetic Disorders: Caused by a mutation in a single gene 1. Autosomal recessive alleles:
Collaborative Study Proposal: Renal Cell Cancer in Lynch Syndrome.
Variant Classification and Reclassification. Introduction This slide presentation covers several topics pertaining to Variant classification, reclassification.
The National Cancer Research Network is part of the National Institute for Health Research CANCER GENETIC TRIALS Leicestershire, Northamptonshire and Rutland.
Robert E. Schoen, MD MPH Associate Professor of Medicine and Epidemiology Division of Gastroenterology University of Pittsburgh Hereditary Colorectal Cancer:
Hereditary Cancer Predisposition: Updates in Genetic Testing
Navigating from Somatic Tumor Testing to Germline Genetic Testing
Kyle Salsbery Genetic Counselor
Susan Domchek, MD University of Pennsylvania
Fostering a Collaborative Approach in the Management of BRCA-Mutated Ovarian Cancer.
What are Microsatellites?
What are reduced penetrance and variable expressivity
New Approaches to Cancer Susceptibility Testing
Genetic Testing Result Means. Before Genetic Testing  The result of genetic testing can be life changing.  It is important for patients and their families.
Hereditary Colorectal Cancer: From Genetic Testing to Prevention
Genetic Testing.
Counseling Patients About Germline BRCA Mutations
BRCA1/2 Genetic Testing: Some Psychological Implications
Biology of hereditary breast and ovarian cancer (HBOC)
HBOC Genetic counseling: major concerns and communication skills
Giovanni Parmigiani, Donald A. Berry, Omar Aguilar 
A, Proportion of variants detected in the MMR genes.
Presentation transcript:

Development of a genetic model predicting the carrier status for mmr-gene mutations Fabio Marroni 1, Piero Benatti 2, Mariapina Montera 3, Daniela Barana 4, Monica Pedroni 2, Margherita Torrini 3, Luca Roncucci 2, Cristina Oliani 4, Cristina Mareni 3, Maurizio Ponz de Leon 2, Generoso Bevilacqua 1 and Silvano Presciuttini 1 1 Università di Pisa 2 Università di Modena 3 Università di Genova 4 Ospedale Maggiore - Verona

Introduction A relevant proportion of HNPCC families is attributable to germline mutations in MLH1 and MSH2 Lifetime risk of developing a CRC is more than 70% in mutation carriers. Female carriers also have a 30% lifetime risk of developing endometrial cancer Early detection of mmr-gene mutations can substantially reduce the lifetime risk of developing cancer Accurate evaluation of the probability that an individual carries a germline pathogenic mutation at MLH1 or MSH2 is therefore essential to help counselors and counselands decide whether testing is appropriate.

“State of the art” The only predictive method currently available has been developed by Wijnen et al. This model was based on logistic regression of 184 families, 47 of which carried a MLH1 or MSH2 mutation. The equation found by these Authors is as follows: log(p/1-p)= *V *V *V 3 – V 1 is the mean age at diagnosis of CRC in all members – V 2 is 1 if at least one endometrial cancer is reported 0 otherwise – V 3 is 1 if the family meet Amsterdam criteria and 0 otherwise

An example: Family F093 Mean age of colon cancer( )/4: V 1 =44.25 No endometrial cancers: V 2 =0 Amsterdam criteria met: V 3 =1 p(mut)=0.35

Validation of Wijnen model Validation of a model requires comparing its predictions in large data sets of families screened for mutations with the results of genetic tests Wijnen model was found to underestimate the risk of carrying a mmr-gene mutation in 509 Finnish families (Loukola et al 1999) We applied Wijnen model to a first set of 105 Italian families, and found the same result (21.4 expected mutations vs 28 observed)

Empirical Models vs Genetic Models Empirical models (e.g. based on logistic regression): – Strongly dependent on the particular data sets that is being analyzed – Unable to cover all special cases with sufficient data Genetic models: – Based on knowledge of relevant genetic parameters.

Development of a genetic model to be implemented in Fastlink In analogy with our previous experience with BRCA genes, we intend to develop a full genetic model for predicting carrier probability of MSH2 and MLH1 mutations This requires knowledge of the following genetic parameters: – Frequency of mutated alleles – Cancer penetrance in carriers and non-carriers

A preliminary version Gene frequency: 1/3139 ( ) as reported by Dunlop et al (2000) Penetrance: as reported by Aarnio et al (1999)

Results and perspectives Our model predicted mutations, compared to 28 actually found. Performance will be further improved by taking into account additional variables: – Molecular data about MSI – Possible differences of expressivity between MLH1 and MSH2 A crucial requirement for the improvement of our model is increasing the number of screened families.